Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.190
-0.005 (-0.42%)
At close: Jul 29, 2026, 4:00 PM EDT
1.229
+0.039 (3.29%)
After-hours: Jul 29, 2026, 7:57 PM EDT
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $258.00K in the quarter ending March 31, 2026, a decrease of -95.61%. This brings the company's revenue in the last twelve months to $61.19M, up 37.24% year-over-year. In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth.
Revenue (ttm)
$61.19M
Revenue Growth
+37.24%
P/S Ratio
1.13
Revenue / Employee
$2,447,440
Employees
25
Market Cap
68.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSPRO News
- 2 days ago - Spero Therapeutics appoints Debra Jeske Zack as chief medical officer - TheFly
- 2 days ago - Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 15 days ago - Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
- 15 days ago - Spero Therapeutics secures $105M non-dilutive financing to develop SP001 - TheFly
- 15 days ago - Spero Therapeutics, Innovent Biologics enter license agreement for SP001 - TheFly
- 15 days ago - Spero Therapeutics, Innovent Biologics announce exclusive IBI355 license pact - TheFly
- 15 days ago - Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties - GlobeNewsWire
- 15 days ago - Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - PRNewsWire